From Oncology October 15, 2022:
Published in The Lancet Oncology 29.09.2022
"This phase III trial evaluated the use of blood ESR1 mutational burden to guide the change of therapy in patients with oestrogen receptor–positive HER2-negative breast cancer. Patients in whom an increase in blood ESR1 mutation levels was detected with no synchronous disease progression were randomised to either continue treatment with first-line aromatase inhibitors and palbociclib or switch to fulvestrant and palbociclib. Patients who switched to fulvestrant-based therapy had significantly longer median progression-free survival than those who remained on the original treatment. Adverse effects were similar between the treatment groups.
These results suggest that circulating tumour DNA may serve as a tool to predict tumour resistance and allow for earlier optimisation of therapy."